Clinical trials: CoVid 19 Positive
COVID-19
Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of NP-101 in treating high-risk participants who have tested positive for Covid-19.
- Trial name
- BOSS-002 (NCT05785390)
- Testing
- NP-101
- Where
- 4 sites in United States
- Volunteers
- 170 people
- Sponsor
- Novatek Pharmaceuticals
Coronavirus Infection, COVID-19
WGS Analysis of COVID-19 Positive Patients
We aim to better understand the mode of action of COVID-19 in the context of its interaction with the host genome through whole-genome sequencing.
- Trial name
- NCT04353401
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Vanda Pharmaceuticals
COVID-19, Infectious Disease
Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects
This is a first in human clinical study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of RQ-01. Adult patients who have tested positive for SARS-CoV-2 virus, have mild symptom(s) of COVID-19 disease…
- Conditions
- COVID-19, Infectious Disease, Symptomatic COVID-19 Infection Laboratory-Confirmed, SARS CoV 2 Infection
- Trial name
- NCT06063330
- Testing
- RQ-001
- Where
- 6 sites in United States
- Volunteers
- 66 people
- Sponsor
- Red Queen Therapeutics, Inc.
Covid19, Novel Coronavirus Pneumonia
The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19
Novel coronavirus pneumonia (NCP) and acute respiratory distress syndrome (ARDS) are both associated with the prevailing upper respiratory tract infections caused by the RNA-containing SARS-CoV2 virus of the genius…
- Conditions
- Covid19, Novel Coronavirus Pneumonia, Acute Respiratory Distress Syndrome
- Trial name
- ARDOXSO (NCT04798716)
- Testing
- MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- AVEM HealthCare
SARS-CoV Infection
A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research
Minimal risk research study: 1. Comparing polyester nasal swabs and foam nasal swabs to detect SARS-CoV-2 virus; 2. Quantifying the development and trajectory of the disease through clinic visits and blood values.
- Trial name
- NCT04327804
- Testing
- Odd/Even birth year intervention groups
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- UnitedHealth Group